<DOC>
	<DOCNO>NCT02684409</DOCNO>
	<brief_summary>This Phase 1 , multiple center , open label , single-dose study otherwise healthy adolescent subject history acute migraine . Subjects receive one Zecuity patch application . Subjects admit 2 hour prior dose Day 1 , remain clinical unit supervision last pharmacokinetic ( PK ) sample obtain . Blood obtain prescribed time PK analysis safety assessment perform , include adverse event monitoring , 12-lead ECG test , patch adhesion evaluation , skin irritation evaluation , vital sign .</brief_summary>
	<brief_title>Safety , Pharmacokinetic , Tolerability Study ZecuityÂ® Adolescent Subjects With History Acute Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject diagnosis migraine headache , without aura Subject subject 's parent legal guardian able read write English Subject must negative drug screen . Female subject eligible participation provide nonchild bear potential started menses ; stable regimen acceptable contraception Subject one acceptable patch application site ( left right upper arm thigh ) relatively hair free scar , tattoo , abrasion Subject must body mass index 5th 84th percentile age sex Subject must nonsmoker Subject must consume alcoholic beverage , poppy seed , grapefruit , and/or grapefruit juice within 72 hour prior admission clinic Additional criterion apply , please contact investigator information Subject suspect confirm cardiovascular disease Subject history epilepsy condition associate lowered seizure threshold Subject Raynaud 's disease Subject history basilar hemiplegic migraine Subject current diagnosis major depressive disorder Subject take nontriptan serotonergic drug include selective serotonin reuptake inhibitor ( SSRIs ) , serotonin norepinephrine reuptake inhibitor ( SNRIs , include Wellbutrin ) , tricyclic antidepressant ( TCAs ) , monoamine oxidase inhibitor ( MAOIs ) preparation contain St. John 's Wort within 1 month prior screen and/or plan start medication study End Study visit Subject history significant allergy hypersensitivity component study patch use study Subject generalize skin irritation disease include eczema , psoriasis , melanoma , acne contact dermatitis Subject positive hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) Female subject pregnant , breast feeding , childbearing potential , use unwilling use effective form contraception Subject know history tolerability issue sumatriptan Subject history ( within 1 year ) current evidence drug alcohol abuse dependence Subject participate clinical study within 30 day screen plan participate another clinical study within 30 day last study visit Subject electrically sensitive ( e.g. , prior iontophoresis adverse outcome relate current deliver device ) . Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>